{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:27:33Z","timestamp":1793597253590,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ard.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:29:51Z","timestamp":1775129391000},"page":"1445-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subclinical psoriatic arthritis: concepts, dilemmas, and research needs"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-0341","authenticated-orcid":false,"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankti","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Carrizo Abarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.03.011_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ard.2026.03.011_bib0002","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/1744666X.2024.2384705","article-title":"Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies","volume":"20","author":"Kharouf","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"10.1016\/j.ard.2026.03.011_bib0003","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.03.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/rheumatology\/keae399","article-title":"Subclinical psoriatic arthritis and disease interception\u2014where are we in 2024?","volume":"64","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2026.03.011_bib0006","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.03.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2026.03.011_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.03.011_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study","volume":"17","author":"Perez-Chada","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000025","article-title":"What makes psoriatic and rheumatoid arthritis so different?","volume":"1","author":"Veale","year":"2015","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2026.03.011_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.43218","article-title":"EULAR\/American College of Rheumatology risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia","volume":"78","author":"van Steenbergen","year":"2026","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102797","article-title":"The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis","volume":"20","author":"Petrovsk\u00e1","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ard.2026.03.011_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.011_bib0014","article-title":"A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis","author":"Deane","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"10348","key":"10.1016\/j.ard.2026.03.011_bib0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ard.2026.03.011_bib0016","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2665-9913(24)00196-6","article-title":"Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial","volume":"6","author":"Dumoulin","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"10429","key":"10.1016\/j.ard.2026.03.011_bib0017","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ard.2026.03.011_bib0018","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3899\/jrheum.2024-1148","article-title":"Degenerative disc disease in young adults with psoriatic arthritis","volume":"52","author":"Kharouf","year":"2025","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.03.011_bib0019","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jbspin.2015.01.016","article-title":"Ultrasound study of entheses in psoriasis patients with or without musculoskeletal symptoms: a prospective study","volume":"82","author":"Acquacalda","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.ard.2026.03.011_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejrad.2007.08.005","article-title":"MR imaging features of foot involvement in patients with psoriasis","volume":"67","author":"Erdem","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ard.2026.03.011_bib0021","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fmed.2020.00487","article-title":"Ultrasound imaging in psoriatic arthritis: what have we learnt in the last five years?","volume":"7","author":"Dubash","year":"2020","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.ard.2026.03.011_bib0022","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3390\/jcm9092929","article-title":"Accuracy of physical examination to detect synovial and extra-synovial pathologies in psoriatic arthritis in comparison to ultrasonography","volume":"9","author":"Gazel","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152639","article-title":"Comparative analysis of disease outcomes: Early vs. late transition from psoriasis to psoriatic arthritis","volume":"71","author":"Kharouf","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2026.03.011_bib0025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ero.2025.12.008","article-title":"Understanding the transition from psoriasis to psoriatic arthritis: the role of targeted therapy","volume":"2","author":"Kharouf","year":"2026","journal-title":"EULAR Rheumatol Open"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0027","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.011_bib0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.03.011_bib0029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","volume":"84","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.03.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:00:22Z","timestamp":1793595622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726001962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0003496726001962"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.011","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subclinical psoriatic arthritis: concepts, dilemmas, and research needs","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}